Report Scope & Overview:
Psychiatric and Nervous Drugs Market was valued at US$ 20 Billion in 2022 and is projected to reach US$ 30 Billion by 2032, registering a CAGR of 7% from 2022 to 2032.
Psychiatric and Nervous Drugs Market Overview:
Global Psychiatric and Nervous Drugs Market research provides insights into consumer behavior, industry trends, and market competition through the use of various research techniques, including surveys, interviews, and data analysis. The industry serves a wide range of clients, including businesses, government agencies, and non-profit organizations. Psychiatric and Nervous Drugs Market is highly diverse, with a range of services and specialties, including quantitative and qualitative research, brand research, product testing, customer satisfaction research, and competitive analysis.
Global Psychiatric and Nervous Drugs Market research provides insights into consumer behavior, industry trends, and market competition through the use of various research techniques, including surveys, interviews, and data analysis. The industry serves a wide range of clients, including businesses, government agencies, and non-profit organizations. Psychiatric and Nervous Drugs Market is highly diverse, with a range of services and specialties, including quantitative and qualitative research, brand research, product testing, customer satisfaction research, and competitive analysis.
Overall, Psychiatric and Nervous Drugs market plays a crucial role in helping businesses and organizations make informed decisions based on data-driven insights. As the demand for data-driven decision-making continues to grow, Psychiatric and Nervous Drugs market research is expected to experience further growth and innovation in the coming years.
DESCIMG1
Psychiatric and Nervous Drugs Market Key Trends
Rise in Mental Health Awareness: There has been a significant increase in awareness and understanding of mental health issues, leading to higher demand for psychiatric and nervous drugs. This trend has been fueled by advocacy efforts, media coverage, and campaigns aimed at reducing stigma associated with mental health conditions.
Telemedicine and Digital Therapeutics: The COVID-19 pandemic accelerated the adoption of telemedicine and digital therapeutics, including mental health apps and online therapy platforms. This trend has led to the development and prescription of digital interventions alongside traditional psychiatric medications.
Personalized Medicine: Advances in genetics and biomarker research have led to a growing interest in personalized medicine for mental health conditions. Tailoring treatment plans based on a patient's genetic makeup and other individual factors has the potential to improve treatment efficacy and minimize side effects.
Drug Repurposing and Novel Approaches: Pharmaceutical companies have been exploring the repurposing of existing drugs for new psychiatric indications, as well as developing novel drugs targeting previously unexplored pathways. This can potentially lead to more effective and innovative treatments.
Focus on Long-Acting Formulations: The development of long-acting formulations (such as injectables) for psychiatric medications aims to improve patient adherence and reduce the frequency of dosing, potentially enhancing treatment outcomes.
Treatment-Resistant Conditions: There has been increased research and development efforts focused on treatment-resistant conditions, such as treatment-resistant depression and schizophrenia. New approaches, including the use of ketamine and other innovative therapies, have been explored.
Growing Geriatric Population: As the global population continues to age, there is a growing need for psychiatric and nervous drugs that cater to the unique needs of the elderly population, including considerations related to interactions with other medications and age-related physiological changes.
Regulatory Changes and Drug Approvals: Regulatory agencies have been working to streamline the approval process for new psychiatric drugs, especially those addressing unmet needs. Expedited pathways and breakthrough designations have been granted to certain drugs showing promising results.
Market Segmentations:Global Psychiatric and Nervous Drugs Market: By Company
• Pfizer
• Ely Lilly
• Actavis
• Mylan
• Randox
• Intellipharmaceutics
• Astrazeneca
• Lundbeck
• Allergan
• GSK
• Otsuka Pharmaceutical
• Takeda
• NHU Group
• Shionogi
• APOTEX
• Chengdu Kanghong Pharmaceutical
• HUAHAI
• Zhejiang Jianfeng
• Beijing Winsunny Pharmaceutical
Global Psychiatric and Nervous Drugs Market: By Type
• Antidepressants
• Anti-anxiety
• Antipsychotic
• Mood Stabilizing
• Stimulant Medications
• Others
Global Psychiatric and Nervous Drugs Market: By Application
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Psychiatric and Nervous Drugs Market: Regional Analysis
All the regional segmentation has been studied based on recent and future trends, and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Psychiatric and Nervous Drugs market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
| Report Attribute/Metric | Details |
| Market Size 2022 | US$ 20 Billion |
| Market Size 2032 | US$ 30 Billion |
| Compound Annual Growth Rate (CAGR) | 7%(2022-2032) |
| Base Year | 2022 |
| Forecast Period | 2023-2032 |
| Historical Data | 2018-2022 |
| Forecast Units | Value (US$ Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| By Type | • Antidepressants • Anti-anxiety • Antipsychotic • Mood Stabilizing • Stimulant Medications • Others |
| By Application | • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies |
| Key Companies Profiled | • Pfizer • Ely Lilly • Actavis • Mylan • Randox • Intellipharmaceutics • Astrazeneca • Lundbeck • Allergan • GSK • Otsuka Pharmaceutical • Takeda • NHU Group • Shionogi • APOTEX • Chengdu Kanghong Pharmaceutical • HUAHAI • Zhejiang Jianfeng • Beijing Winsunny Pharmaceutical |
| Regions and Key Countries Covered | U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America |
| Customization Scope | Available on Request |
Reasons to Purchase Psychiatric and Nervous Drugs Market Report:
• To gain insights into market trends and dynamics: this reports provide valuable insights into industry trends and dynamics, including market size, growth rates, and key drivers and challenges.
• To identify key players and competitors: this research reports can help businesses identify key players and competitors in their industry, including their market share, strategies, and strengths and weaknesses.
• To understand consumer behavior: this research reports can provide valuable insights into consumer behavior, including their preferences, purchasing habits, and demographics.
• To evaluate market opportunities: this research reports can help businesses evaluate market opportunities, including potential new products or services, new markets, and emerging trends.
• To make informed business decisions: this research reports provide businesses with data-driven insights that can help them make informed business decisions, including strategic planning, product development, and marketing and advertising strategies.
Objectives of Psychiatric and Nervous Drugs Market Study:
The objectives of Psychiatric and Nervous Drugs market research report may vary depending on the specific needs and goals of the business or organization commissioning the report. However, some common objectives of market research reports include:
• Understanding the market size and potential: One of the primary objectives of Psychiatric and Nervous Drugs market research is to understand the size and potential of a particular market. This includes analyzing market trends and dynamics, identifying key players and competitors, and assessing the demand for products or services.
• Identifying target customers and segments: this market research reports can help businesses identify and understand their target customers and market segments, including their preferences, behaviors, and demographics. This information can be used to develop targeted marketing and advertising strategies.
• Evaluating product or service performance: this market research reports can provide valuable insights into the performance of products or services, including customer satisfaction, product usage, and product quality. This information can be used to improve products or services and enhance customer satisfaction.
• Assessing market opportunities and threats: this market research reports can help businesses identify potential market opportunities and threats, including emerging trends, competitive threats, and new market entrants. This information can be used to develop strategic plans and make informed business decisions.
• Developing effective marketing and advertising strategies: this market research reports can help businesses develop effective marketing and advertising strategies by providing insights into customer preferences and behavior, competitive dynamics, and market trends. This can help businesses improve brand awareness, customer engagement, and overall marketing effectiveness.
Frequently Asked Questions
Psychiatric and Nervous Drugs Market was valued at US$ 20 Billion in 2022 and is projected to reach US$ 30 Billion by 2032, registering a CAGR of 7% from 2022 to 2032.
The major drivers of growth in the psychiatric and nervous drugs market include increasing mental health awareness, a rise in the prevalence of mental disorders globally, and ongoing research and development leading to new treatment options.
The COVID-19 pandemic has accelerated the adoption of telemedicine and digital mental health solutions. It has also highlighted the need for accessible and effective treatments for mental health conditions due to the increased stress and anxiety caused by the pandemic.
Regulatory agencies play a crucial role in evaluating and approving psychiatric drugs for safety and efficacy. They may grant expedited pathways or breakthrough designations for innovative treatments addressing unmet needs.
TABLE OF CONTENT
1 Psychiatric and Nervous Drugs Market Overview
1.1 Product Overview and Scope of Psychiatric and Nervous Drugs
1.2 Psychiatric and Nervous Drugs Segment by Type
1.2.1 Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Antidepressants
1.2.3 Anti-anxiety
1.2.4 Antipsychotic
1.2.5 Mood Stabilizing
1.2.6 Stimulant Medications
1.2.7 Others
1.3 Psychiatric and Nervous Drugs Segment by Application
1.3.1 Global Psychiatric and Nervous Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Psychiatric and Nervous Drugs Market Size Estimates and Forecasts
1.4.1 Global Psychiatric and Nervous Drugs Revenue 2017-2032
1.4.2 Global Psychiatric and Nervous Drugs Sales 2017-2032
1.4.3 Global Psychiatric and Nervous Drugs Market Average Price (2017-2032)
1.5 Assumptions and Limitations
2 Psychiatric and Nervous Drugs Market Competition by Manufacturers
2.1 Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2017-2023)
2.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Manufacturers (2017-2023)
2.3 Global Psychiatric and Nervous Drugs Average Price by Manufacturers (2017-2023)
2.4 Global Psychiatric and Nervous Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Psychiatric and Nervous Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Psychiatric and Nervous Drugs, Product Type & Application
2.7 Psychiatric and Nervous Drugs Market Competitive Situation and Trends
2.7.1 Psychiatric and Nervous Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Psychiatric and Nervous Drugs Players Market Share by Revenue
2.7.3 Global Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Psychiatric and Nervous Drugs Retrospective Market Scenario by Region
3.1 Global Psychiatric and Nervous Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Psychiatric and Nervous Drugs Global Psychiatric and Nervous Drugs Sales by Region: 2017-2032
3.2.1 Global Psychiatric and Nervous Drugs Sales by Region: 2017-2023
3.2.2 Global Psychiatric and Nervous Drugs Sales by Region: 2023-2032
3.3 Global Psychiatric and Nervous Drugs Global Psychiatric and Nervous Drugs Revenue by Region: 2017-2032
3.3.1 Global Psychiatric and Nervous Drugs Revenue by Region: 2017-2023
3.3.2 Global Psychiatric and Nervous Drugs Revenue by Region: 2023-2032
3.4 North America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.4.1 North America Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.4.2 North America Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.4.3 North America Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.5.1 Europe Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.5.2 Europe Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.5.3 Europe Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.6.2 Asia Pacific Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.6.3 Asia Pacific Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.7.1 Latin America Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.7.2 Latin America Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.7.3 Latin America Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.8.2 Middle East and Africa Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.8.3 Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Psychiatric and Nervous Drugs Sales by Type (2017-2032)
4.1.1 Global Psychiatric and Nervous Drugs Sales by Type (2017-2023)
4.1.2 Global Psychiatric and Nervous Drugs Sales by Type (2023-2032)
4.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Type (2017-2032)
4.2 Global Psychiatric and Nervous Drugs Revenue by Type (2017-2032)
4.2.1 Global Psychiatric and Nervous Drugs Revenue by Type (2017-2023)
4.2.2 Global Psychiatric and Nervous Drugs Revenue by Type (2023-2032)
4.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2017-2032)
4.3 Global Psychiatric and Nervous Drugs Price by Type (2017-2032)
5 Segment by Application
5.1 Global Psychiatric and Nervous Drugs Sales by Application (2017-2032)
5.1.1 Global Psychiatric and Nervous Drugs Sales by Application (2017-2023)
5.1.2 Global Psychiatric and Nervous Drugs Sales by Application (2023-2032)
5.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Application (2017-2032)
5.2 Global Psychiatric and Nervous Drugs Revenue by Application (2017-2032)
5.2.1 Global Psychiatric and Nervous Drugs Revenue by Application (2017-2023)
5.2.2 Global Psychiatric and Nervous Drugs Revenue by Application (2023-2032)
5.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2017-2032)
5.3 Global Psychiatric and Nervous Drugs Price by Application (2017-2032)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.1.4 Pfizer Psychiatric and Nervous Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Corporation Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.2.4 Ely Lilly Psychiatric and Nervous Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Corporation Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.3.4 Actavis Psychiatric and Nervous Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Mylan Psychiatric and Nervous Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Corporation Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.5.4 Randox Psychiatric and Nervous Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Corporation Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.6.4 Intellipharmaceutics Psychiatric and Nervous Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.6.1 Astrazeneca Corporation Information
6.6.2 Astrazeneca Description and Business Overview
6.6.3 Astrazeneca Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Astrazeneca Psychiatric and Nervous Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Corporation Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.8.4 Lundbeck Psychiatric and Nervous Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Corporation Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.9.4 Allergan Psychiatric and Nervous Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.10.4 GSK Psychiatric and Nervous Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Corporation Information
6.11.2 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.11.3 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.11.4 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda Psychiatric and Nervous Drugs Description and Business Overview
6.12.3 Takeda Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.12.4 Takeda Psychiatric and Nervous Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Corporation Information
6.13.2 NHU Group Psychiatric and Nervous Drugs Description and Business Overview
6.13.3 NHU Group Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.13.4 NHU Group Psychiatric and Nervous Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Corporation Information
6.14.2 Shionogi Psychiatric and Nervous Drugs Description and Business Overview
6.14.3 Shionogi Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.14.4 Shionogi Psychiatric and Nervous Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Corporation Information
6.15.2 APOTEX Psychiatric and Nervous Drugs Description and Business Overview
6.15.3 APOTEX Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.15.4 APOTEX Psychiatric and Nervous Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 Chengdu Kanghong Pharmaceutical
6.16.1 Chengdu Kanghong Pharmaceutical Corporation Information
6.16.2 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.16.3 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.16.4 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
6.17 HUAHAI
6.17.1 HUAHAI Corporation Information
6.17.2 HUAHAI Psychiatric and Nervous Drugs Description and Business Overview
6.17.3 HUAHAI Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.17.4 HUAHAI Psychiatric and Nervous Drugs Product Portfolio
6.17.5 HUAHAI Recent Developments/Updates
6.18 Zhejiang Jianfeng
6.18.1 Zhejiang Jianfeng Corporation Information
6.18.2 Zhejiang Jianfeng Psychiatric and Nervous Drugs Description and Business Overview
6.18.3 Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.18.4 Zhejiang Jianfeng Psychiatric and Nervous Drugs Product Portfolio
6.18.5 Zhejiang Jianfeng Recent Developments/Updates
6.19 Beijing Winsunny Pharmaceutical
6.19.1 Beijing Winsunny Pharmaceutical Corporation Information
6.19.2 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.19.3 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.19.4 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.19.5 Beijing Winsunny Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Psychiatric and Nervous Drugs Industry Chain Analysis
7.2 Psychiatric and Nervous Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Psychiatric and Nervous Drugs Production Mode & Process
7.4 Psychiatric and Nervous Drugs Sales and Marketing
7.4.1 Psychiatric and Nervous Drugs Sales Channels
7.4.2 Psychiatric and Nervous Drugs Distributors
7.5 Psychiatric and Nervous Drugs Customers
8 Psychiatric and Nervous Drugs Market Dynamics
8.1 Psychiatric and Nervous Drugs Industry Trends
8.2 Psychiatric and Nervous Drugs Market Drivers
8.3 Psychiatric and Nervous Drugs Market Challenges
8.4 Psychiatric and Nervous Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Psychiatric and Nervous Drugs
1.2 Psychiatric and Nervous Drugs Segment by Type
1.2.1 Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Antidepressants
1.2.3 Anti-anxiety
1.2.4 Antipsychotic
1.2.5 Mood Stabilizing
1.2.6 Stimulant Medications
1.2.7 Others
1.3 Psychiatric and Nervous Drugs Segment by Application
1.3.1 Global Psychiatric and Nervous Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Psychiatric and Nervous Drugs Market Size Estimates and Forecasts
1.4.1 Global Psychiatric and Nervous Drugs Revenue 2017-2032
1.4.2 Global Psychiatric and Nervous Drugs Sales 2017-2032
1.4.3 Global Psychiatric and Nervous Drugs Market Average Price (2017-2032)
1.5 Assumptions and Limitations
2 Psychiatric and Nervous Drugs Market Competition by Manufacturers
2.1 Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2017-2023)
2.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Manufacturers (2017-2023)
2.3 Global Psychiatric and Nervous Drugs Average Price by Manufacturers (2017-2023)
2.4 Global Psychiatric and Nervous Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Psychiatric and Nervous Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Psychiatric and Nervous Drugs, Product Type & Application
2.7 Psychiatric and Nervous Drugs Market Competitive Situation and Trends
2.7.1 Psychiatric and Nervous Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Psychiatric and Nervous Drugs Players Market Share by Revenue
2.7.3 Global Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Psychiatric and Nervous Drugs Retrospective Market Scenario by Region
3.1 Global Psychiatric and Nervous Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Psychiatric and Nervous Drugs Global Psychiatric and Nervous Drugs Sales by Region: 2017-2032
3.2.1 Global Psychiatric and Nervous Drugs Sales by Region: 2017-2023
3.2.2 Global Psychiatric and Nervous Drugs Sales by Region: 2023-2032
3.3 Global Psychiatric and Nervous Drugs Global Psychiatric and Nervous Drugs Revenue by Region: 2017-2032
3.3.1 Global Psychiatric and Nervous Drugs Revenue by Region: 2017-2023
3.3.2 Global Psychiatric and Nervous Drugs Revenue by Region: 2023-2032
3.4 North America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.4.1 North America Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.4.2 North America Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.4.3 North America Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.5.1 Europe Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.5.2 Europe Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.5.3 Europe Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.6.2 Asia Pacific Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.6.3 Asia Pacific Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.7.1 Latin America Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.7.2 Latin America Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.7.3 Latin America Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Psychiatric and Nervous Drugs Market Size by Country: 2018 VS 2023 VS 2032
3.8.2 Middle East and Africa Psychiatric and Nervous Drugs Sales by Country (2017-2032)
3.8.3 Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country (2017-2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Psychiatric and Nervous Drugs Sales by Type (2017-2032)
4.1.1 Global Psychiatric and Nervous Drugs Sales by Type (2017-2023)
4.1.2 Global Psychiatric and Nervous Drugs Sales by Type (2023-2032)
4.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Type (2017-2032)
4.2 Global Psychiatric and Nervous Drugs Revenue by Type (2017-2032)
4.2.1 Global Psychiatric and Nervous Drugs Revenue by Type (2017-2023)
4.2.2 Global Psychiatric and Nervous Drugs Revenue by Type (2023-2032)
4.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2017-2032)
4.3 Global Psychiatric and Nervous Drugs Price by Type (2017-2032)
5 Segment by Application
5.1 Global Psychiatric and Nervous Drugs Sales by Application (2017-2032)
5.1.1 Global Psychiatric and Nervous Drugs Sales by Application (2017-2023)
5.1.2 Global Psychiatric and Nervous Drugs Sales by Application (2023-2032)
5.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Application (2017-2032)
5.2 Global Psychiatric and Nervous Drugs Revenue by Application (2017-2032)
5.2.1 Global Psychiatric and Nervous Drugs Revenue by Application (2017-2023)
5.2.2 Global Psychiatric and Nervous Drugs Revenue by Application (2023-2032)
5.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2017-2032)
5.3 Global Psychiatric and Nervous Drugs Price by Application (2017-2032)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.1.4 Pfizer Psychiatric and Nervous Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Corporation Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.2.4 Ely Lilly Psychiatric and Nervous Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Corporation Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.3.4 Actavis Psychiatric and Nervous Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Mylan Psychiatric and Nervous Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Corporation Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.5.4 Randox Psychiatric and Nervous Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Corporation Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.6.4 Intellipharmaceutics Psychiatric and Nervous Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.6.1 Astrazeneca Corporation Information
6.6.2 Astrazeneca Description and Business Overview
6.6.3 Astrazeneca Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Astrazeneca Psychiatric and Nervous Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Corporation Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.8.4 Lundbeck Psychiatric and Nervous Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Corporation Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.9.4 Allergan Psychiatric and Nervous Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.10.4 GSK Psychiatric and Nervous Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Corporation Information
6.11.2 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.11.3 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.11.4 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda Psychiatric and Nervous Drugs Description and Business Overview
6.12.3 Takeda Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.12.4 Takeda Psychiatric and Nervous Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Corporation Information
6.13.2 NHU Group Psychiatric and Nervous Drugs Description and Business Overview
6.13.3 NHU Group Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.13.4 NHU Group Psychiatric and Nervous Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Corporation Information
6.14.2 Shionogi Psychiatric and Nervous Drugs Description and Business Overview
6.14.3 Shionogi Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.14.4 Shionogi Psychiatric and Nervous Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Corporation Information
6.15.2 APOTEX Psychiatric and Nervous Drugs Description and Business Overview
6.15.3 APOTEX Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.15.4 APOTEX Psychiatric and Nervous Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 Chengdu Kanghong Pharmaceutical
6.16.1 Chengdu Kanghong Pharmaceutical Corporation Information
6.16.2 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.16.3 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.16.4 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
6.17 HUAHAI
6.17.1 HUAHAI Corporation Information
6.17.2 HUAHAI Psychiatric and Nervous Drugs Description and Business Overview
6.17.3 HUAHAI Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.17.4 HUAHAI Psychiatric and Nervous Drugs Product Portfolio
6.17.5 HUAHAI Recent Developments/Updates
6.18 Zhejiang Jianfeng
6.18.1 Zhejiang Jianfeng Corporation Information
6.18.2 Zhejiang Jianfeng Psychiatric and Nervous Drugs Description and Business Overview
6.18.3 Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.18.4 Zhejiang Jianfeng Psychiatric and Nervous Drugs Product Portfolio
6.18.5 Zhejiang Jianfeng Recent Developments/Updates
6.19 Beijing Winsunny Pharmaceutical
6.19.1 Beijing Winsunny Pharmaceutical Corporation Information
6.19.2 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
6.19.3 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2023)
6.19.4 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.19.5 Beijing Winsunny Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Psychiatric and Nervous Drugs Industry Chain Analysis
7.2 Psychiatric and Nervous Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Psychiatric and Nervous Drugs Production Mode & Process
7.4 Psychiatric and Nervous Drugs Sales and Marketing
7.4.1 Psychiatric and Nervous Drugs Sales Channels
7.4.2 Psychiatric and Nervous Drugs Distributors
7.5 Psychiatric and Nervous Drugs Customers
8 Psychiatric and Nervous Drugs Market Dynamics
8.1 Psychiatric and Nervous Drugs Industry Trends
8.2 Psychiatric and Nervous Drugs Market Drivers
8.3 Psychiatric and Nervous Drugs Market Challenges
8.4 Psychiatric and Nervous Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
Ely Lilly
Actavis
Mylan
Randox
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Chengdu Kanghong Pharmaceutical
HUAHAI
Zhejiang Jianfeng
Beijing Winsunny Pharmaceutical
In Vitro Diagnostics Quality Control Market
Global In Vitro Diagnostics Quality Control Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Ileostomy Market
Global Ileostomy Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Human Papillomavirus Vaccine Market
Global Human Papillomavirus Vaccine Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast
Hospital Acquired Pneumonia Drugs Market
Global Hospital Acquired Pneumonia Drugs Market Size, Share, Trends, Growth, Industry Analysis, By Segmentations, Key Players, Revenue, Future Outlook & Forecast